CALGB 90202 - Randomized Double Blind, Placebo Controlled Phase 3 Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone
GCC 0605 - A Phase II Study Evaluating Bone Marrow-Sparing, Image-Guided Pelvic Intensity-Modulated Radiotherapy (IMRT) with Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients with High Risk, Non-Metastatic Prostate Cancer.
GCC 0703 - A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (ECOG2805)
GCC 0752 - A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
GCC 0755 - A Phase II, Randomized, Open-Label, Pilot Study to Evaulate the Safety and the Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease. D8180C00034
GCC 0758 - A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer
GCC 0771 - A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy
GCC 0783 - A Randomized, Phase II Trial of AZD2171, Docetaxel, and Prednisone Compared to Docetaxel and Prednisone in Patients with Metastatic, Hormone Refractory Prostate Cancer
GCC 0785 - A Randomized Phase II Study of Docetaxel +/- ZD6474 (Zactima) in Metastatic Transitional Cell Carcinoma
GCC 0798 - Randomized Study of Larotaxel + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
GCC 0826 - A Multicenter, Randomized, Double-Blind, Phase 3 Study of Sunitinib Plus Prednisone Versus Prednisone in Patients with Progressive Metastatic Hormone-Refractory Prostate Cancer After Failure of a Docetaxel-Based Chemotherapy Regimen
GCC 0827 - A Phase II trial of Avastin, docetaxel and androgen deprivation followed by continued Avastin and androgen deprivation for men with a rising PSA after local therapy
GCC 0843 - A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Testosterone Replacement in Men with Non-Metastatic Castrate Resistant Prostate Cancer
GCC 0915 - RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736)
GCC 0917 - 0917 GCC: A Phase 1, Multicenter, Open-label, Dose-escalation, Multidose Study of MDX 1203 in Subjects with Advanced/Recurrent Clear Cell Renal Cell Carcinoma
GCC0797 - A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) Who Have Failed Docetaxel-Based Chemotherapy
RTOG 0232 - A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma
RTOG 0526 - A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy
RTOG 0534 - A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy
RTOG P-0126 - A Phase III Randomized Study of High Dose 3D-CRT Versus Standard Dose 3D-CRT In Patients Treated for Localized Prostate Cancer
RTOG-0415 - A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT In Patients With Favorable-Risk Prostate Cancer
Email this Page
Print this Page
